Magali Haas, MD, PhD, MSE
CEO & President, Cohen Veterans Bioscience
Dr. Haas founded Orion Bionetworks in July 2012 and serves as its CEO and President. Orion Bionetworks was transformed to Cohen Veterans Bioscience in 2015 to specifically dedicate research to improving the detection and treatment of post-traumatic stress (PTS) and traumatic brain injury (TBI) and related co-morbidities so that the burden of these conditions may be lessened on service members, veterans, and their families.
Magali has over 15 years of pharmaceutical executive and clinical research experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in medical marketing, full clinical development, early development, and translational and biomarker sciences in psychiatry and neurology. She successfully filed NDAs in the US and Europe for risperidone indications in Autism, Adolescent Schizophrenia, Juvenile Bipolar Disorder and Conduct Disorders. She also led Development Teams evaluating compounds for Depression, Neuropathic Pain, Epilepsy, and Migraine Disorder.
She served 3 years as Chief Science and Technology Officer for One Mind for Research, a nonprofit organization launched in May 2012 by Patrick J Kennedy. She orchestrated the launch of One Mind’s seminal programs, Apollo, an informatics research portal and, Gemini, an international TBI/PTSD research program.
As an “intrapreneur” at J&J she established the first Neuroscience Translational Medicine & Integrative Solutions department, and co-founded the first Companion Diagnostics Center of Excellence as well as J&J’s Healthcare Innovation team. She serves on several advisory boards including Brain Canada, Prophase, Pear Therapeutics, PAASP and IMEC for nanoelectronics.
Magali earned her BS in bioengineering from the University of Pennsylvania, an MS in biomedical engineering from Rutgers University, New Jersey, and her MD PhD with distinction in neuroscience from Albert Einstein College of Medicine, New York. “A change-maker dedicated to revolutionizing care for brain disease” – our President and CEO Magali Haas has been named one of the 100 most inspiring people in the life sciences sector.
Cohen Veterans Bioscience this week announced a groundbreaking partnership with Veterans Health Administration (VA) to advance the diagnosis and treatment of trauma-related brain disorders and, with the Broad Institute’s Stanley Center for Psychiatric Research, presented topline results of the largest study of genetic markers for post-traumatic stress disorder (PTSD). An area of great unmet need, there are millions of individuals suffering with PTSD and traumatic brain injury (TBI) with few proven diagnostic tools or treatments.
VA Partnership for brain-trauma diagnostics and biomarkers. Announced May 17 at the VA’s second annual Brain Trust: Pathways to InnoVAtion in Boston, this partnership will capitalize on recent advances in brain imaging, genetics and other areas that are bringing the previously unseen impact of PTSD and traumatic brain injury (TBI) into focus to discover and support development of first-generation validated biomarkers and diagnostics for PTSD and TBI.
Topline Data on genetic markers of PTSD risk. A presentation at the Society of Biological Psychiatry annual conference in San Diego on May 18, marks a milestone in the shared commitment of Cohen Veterans Bioscience and the Broad Institute to discover genetic markers of PTSD risk.